Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract #887: Genetic and expression changes associated with ellipticine-resistance in high-risk neuroblastoma cell line

Pavel Procházka, Jitka Poljakova, Antonin Libra, Martin Buncek, Jan Hrabeta, Marie Stiborova and Tomas Eckschlager
Pavel Procházka
Charles University in Prague - 2nd Medical School, Prague, Czech Republic; Charles University in Prague - Faculty of Science, Prague, Czech Republic; Generi Biotech, s. r. o., Hradec Kralove, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jitka Poljakova
Charles University in Prague - 2nd Medical School, Prague, Czech Republic; Charles University in Prague - Faculty of Science, Prague, Czech Republic; Generi Biotech, s. r. o., Hradec Kralove, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonin Libra
Charles University in Prague - 2nd Medical School, Prague, Czech Republic; Charles University in Prague - Faculty of Science, Prague, Czech Republic; Generi Biotech, s. r. o., Hradec Kralove, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Buncek
Charles University in Prague - 2nd Medical School, Prague, Czech Republic; Charles University in Prague - Faculty of Science, Prague, Czech Republic; Generi Biotech, s. r. o., Hradec Kralove, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Hrabeta
Charles University in Prague - 2nd Medical School, Prague, Czech Republic; Charles University in Prague - Faculty of Science, Prague, Czech Republic; Generi Biotech, s. r. o., Hradec Kralove, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie Stiborova
Charles University in Prague - 2nd Medical School, Prague, Czech Republic; Charles University in Prague - Faculty of Science, Prague, Czech Republic; Generi Biotech, s. r. o., Hradec Kralove, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomas Eckschlager
Charles University in Prague - 2nd Medical School, Prague, Czech Republic; Charles University in Prague - Faculty of Science, Prague, Czech Republic; Generi Biotech, s. r. o., Hradec Kralove, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

Neuroblastoma is the most frequent extra-cranial tumor in children and is a major cause of death from neoplasia in infancy. One of the main causes of chemotherapy failure is the rise of drug-resistance. The aim of our work was a genetic and expression study of neuroblastoma cell line resistant to ellipticine (UKF-NB-4ELLI) compared to sensitive cell line (UKF-NB-4). Ellipticine is cytostatic drug used in metastatic breast cancer and AML. UKF-NB-4ELLI was prepared by long-term cultivation of UKF-NB-4 cell line with increasing concentrations of ellipticine. UKF-NB-4ELLI has decreased tumorigenicity and slowed growth in vivo in nunu mice in comparison to UKF-NB-4. The prevalent mechanisms of ellipticine antitumor activities were suggested to be its intercalation into DNA and inhibition of topoisomerase II. Ellipticine also covalently binds to DNA after being enzymatically activated by cytochromes P450 (CYP) or peroxidases, suggesting a third possible mechanism of action. We used comparative genomic hybridization to compare DNA from UKF-NB-4 with that of normal human DNA and DNA from UKF-NB-4ELLI with that of the parent UKF-NB-4. Fluorescence in situ hybridization was used for verification of genetic changes. For expression profile we used expression-microarray and for verification expression changes RT PCR. In UKF-NB-4, we identified trisomy in the 7th chromosome with a gain of 7q21, where genes of MDR1 (protein product P-glycoprotein - P-gp) and CYP3A are located. The UKF-NB-4ELLI has trisomy of the 7th chromosome with no other changes (loss of 7q21 gain). UKF-NB-4DOXO, resistant to doxorubicin, has a gain of MDR1 gene and a high P-gp expression. In the UKF-NB-4ELLI, no differences in expression of P-gp compared to UKF-NB-4 were found. Also genes of the two ellipticine-oxidizing cytochromes P450, CYP1A1 and CYP1B1, localized in area 15q22-24 and 2p21 respectively, did not change. Together it suggests that resistance to ellipticine in UKF-NB-4ELLI is not caused by a change in metabolic or efflux activity. However, UK-NB-4 has a gain of topoisomerase II (TOPO2), while UKF-NB-4ELLI has lost one gene copy and a variety of genes corresponding to trisomy of chromosome 17. Expression of TOPO2 was also decreased. Another ellipticine-activating enzyme is myeloperoxidase (located in 17q23). UKF-NB-4 has a gain of 17q23. UKF-NB-4ELLI has lost one copy, but still has a 17q23 gain. We found three changes that might explain the drug-resistance to ellipticine. The first one is deletion of BAX gene (19q13.33), that codes apoptotic protein Bax, the second one is increased expression of antiapoptotic protein Bcl-2 and the third one is decreased expression of TOPO2. Grant support: GAUK 7926/2007, IGA MZ 1A8696-4/2005 and MSM0021620813.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 887.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #887: Genetic and expression changes associated with ellipticine-resistance in high-risk neuroblastoma cell line
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #887: Genetic and expression changes associated with ellipticine-resistance in high-risk neuroblastoma cell line
Pavel Procházka, Jitka Poljakova, Antonin Libra, Martin Buncek, Jan Hrabeta, Marie Stiborova and Tomas Eckschlager
Cancer Res May 1 2009 (69) (9 Supplement) 887;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #887: Genetic and expression changes associated with ellipticine-resistance in high-risk neuroblastoma cell line
Pavel Procházka, Jitka Poljakova, Antonin Libra, Martin Buncek, Jan Hrabeta, Marie Stiborova and Tomas Eckschlager
Cancer Res May 1 2009 (69) (9 Supplement) 887;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Mechanisms of Drugs Based on p53 and Novel Cellular Pathways -- Poster Presentations - Proffered Abstracts

  • Abstract #884: Mechanism of action of PNC-27/-28 anti-cancer peptides
  • Abstract #886: Biological effects of a novel series of dicoumarol analogues that act as inhibitors of NQO1
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement